Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting in symptoms of facial flushing, swollen bumps on the skin surface, and a burning ...

Please provide your email address to receive an email when new articles are posted on . DFD-29 showed safety and efficacy in two phase 3 clinical rosacea trials. Significant improvements in IGA, total ...

Please provide your email address to receive an email when new articles are posted on . Journey Medical Corporation has begun the first of two phase 3 trials evaluating DFD-29 for the treatment of ...

NEW YORK, Sept 26 (Reuters) - CollaGenex Pharmaceuticals Inc said on Wednesday it is ending development of its drug incyclinide for treating the inflammatory skin condition rosacea after a mid-stage ...

Affecting up to 1 in 10 people worldwide, rosacea has a complex pathophysiology that remains inadequately understood, and research has hinted at multiple inflammatory and immune mediated processes ...

SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...

The medication can be taken with or without food, though ingestion of food along with Emrosi may help reduce the risk of esophageal irritation and ulceration. Emrosi ™ (minocycline hydrochloride ...

SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the ...

Epsolay is a topical cream that utilizes a patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules. The Food and Drug Administration (FDA) has approved Epsolay ...

Fortress Biotech announces Emrosi™ launch for rosacea, Checkpoint's acquisition by Sun Pharma, and CUTX-101 NDA acceptance for Menkes disease. Fortress Biotech, Inc. has announced a commercial launch ...

DUBLIN, Oct. 6, 2020 /PRNewswire/ -- The "Europe Rosacea Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...

State Medicaid formularies demonstrate significant variability in rosacea treatment coverage, with only 10% of states offering unrestricted access to basic therapeutic options, in an analysis of ...